Gastric Outlet Obstruction (GOO) — Surgical Perspective

Definition & Overview

Etiology & Differential Diagnosis

Pathophysiology

• Acute/reversible: Edema and spasm around an active pyloric channel or duodenal ulcer
• Chronic/irreversible: Fibrosis, scarring, and gastric atony from repeated ulceration and healing

Hypokalemic hypochloremic metabolic alkalosis — from loss of H⁺ and Cl⁻, with compensatory renal HCO₃⁻ retention and K⁺ loss

Clinical Features

• Nausea and nonbilious vomiting (often of undigested food from hours/days prior)
• Epigastric distension and fullness
• Early satiety
• Weight loss and malnutrition
• Succussion splash on abdominal auscultation (retained gastric contents)
• Dehydration in high-grade obstruction

Investigations

1. Endoscopy (EGD) with biopsy — mandatory; identifies intrinsic lesion, excludes malignancy, allows therapeutic intervention; stomach must be decompressed/fasted first
2. CT abdomen — cross-sectional imaging is usually first step; identifies extrinsic compression (pancreatic mass, nodes), dilated stomach, nature of obstruction
3. Upper GI fluoroscopy with oral barium — useful for characterizing the stricture geometry
4. Endoscopic ultrasound (EUS) — if malignancy suspected or EUS-guided therapy planned
5. Saline load test (historical): 750 mL saline via NGT; aspiration >400 mL at 30 min suggests mechanical obstruction; now less used, but serial measurement (residual <200 mL = resolution) may guide response to medical treatment
6. Labs: electrolytes, CBC, LFTs, amylase, serum gastrin if ZES suspected

Management

General Principles (Multidisciplinary)

1. Decompress stomach (large-bore NGT)
2. Correct electrolyte/fluid abnormalities (particularly hypokalemic hypochloremic alkalosis)
3. Nutritional support (IV if necessary; nasojejunal feeds once feasible)
4. IV PPIs — reduce gastric secretions
5. Specific treatment according to definitive diagnosis

Benign GOO (PUD-related)

Non-operative / Endoscopic

• H. pylori eradication + NSAID cessation → most will respond to acid suppression initially
• Endoscopic balloon dilation may delay surgery for 1–2 years in ~50% of patients with benign GOO from duodenal ulcer
• Most patients requiring hospitalization or repeated dilation will ultimately require surgery

Surgical Options

1. Vagotomy + Antrectomy (V/A) — Gold Standard

• Procedure: Truncal vagotomy + antrectomy + Billroth II (antecolic isoperistaltic gastrojejunostomy) reconstruction
• Advantages: Lowest ulcer recurrence rate; confirms benign diagnosis by resecting the obstruction
• Disadvantages: Operative mortality ~2%; higher technical complexity; difficult duodenal stump if ulcer penetrates posteriorly
• Reconstruction: Billroth II (antecolic, isoperistaltic, afferent loop on greater curvature side). Roux-en-Y is avoided with a large gastric remnant due to risk of marginal ulceration and delayed gastric emptying
• Key technical points:
  • Thick-walled chronically obstructed stomach — use appropriately large staple cartridges to prevent dehiscence
  • The outlet obstruction should be resected and included in the specimen
  • If the obstruction is prepyloric, ensure the distal staple line is truly distal to the pylorus to avoid retained antrum syndrome
  • If ulcer is in the 2nd portion of the duodenum, distal gastrectomy may be hazardous — consider HPB consultation; cancer must be excluded if the obstruction site is left in situ

2. Vagotomy + Gastrojejunostomy (V/GJ) — Good Alternative

• Procedure: Truncal or posterior truncal + anterior HSV vagotomy + loop gastrojejunostomy to the dependent greater curvature
• Advantages:
  • Lower operative mortality
  • Can be performed laparoscopically readily
  • Reversible if dumping becomes intolerable
• Disadvantages:
  • Obstructing cancer may be missed (no resection of the obstructing lesion)
  • Risk of marginal ulcer
  • Patients need close 2-year follow-up; if not doing well, re-exploration and conversion to distal gastrectomy should be considered

Gold standard = V/A; V/GJ is a good alternative with lower mortality and laparoscopic feasibility. — Current Surgical Therapy 14e

Managing the Difficult Duodenal Stump

• Sew the anterior edge of the open duodenum to the proximal/distal lip of the ulcer on the pancreas with interrupted sutures
• Test closure by distending duodenum with air via NG tube
• Cover with vascularized omentum + place multiple closed-suction drains
• Duodenal decompression: retrograde tube via proximal jejunum; or lateral duodenostomy; or NG tube threaded through GJ into afferent limb
• Avoid placing a tube directly into the end of the duodenal stump (always leaks around it)

Malignant GOO

Endoscopic Options

• Self-Expandable Metal Stent (SEMS) via EGD: ~90% of patients can tolerate a soft/regular diet after successful placement. Uncovered SEMS preferred for tumor-in-growth resistance; covered SEMS can be re-stented. Biliary stenting should be done before duodenal stenting (biliary access is technically difficult after duodenal SEMS placement)
• EUS-guided gastroenterostomy (EUS-GE): emerging technique — highly effective for benign or malignant GOO; increasing evidence supports use for both

Surgical Option: Gastrojejunostomy (GJ)

• Retrocolic or antecolic loop/Roux-en-Y gastrojejunostomy
• Open vs. laparoscopic: laparoscopic GJ allows more rapid initiation of systemic anticancer therapy
• Presence of a duodenal stent makes subsequent pancreaticoduodenectomy (Whipple) technically more difficult

Decision Algorithm for Malignant GOO (Pancreatic/Periampullary Cancer)

A prophylactic GJ at the time of open biliary bypass (for found-unresectable disease) is generally advisable even in asymptomatic patients, given the high probability of future duodenal obstruction from tumor progression. — Current Surgical Therapy 14e

Postoperative Management

• High-dose PPIs in the early postoperative period
• Long-term PPI therapy if: chronic aspirin/NSAIDs required, anticoagulation, H. pylori not eradicated
• Smoking cessation — imperative to prevent recurrence
• If NSAIDs are medically necessary: consider selective COX-2 inhibitor + long-term PPI
• Monitor for early rebleeding (upper endoscopy + CT angiography/standard arteriography)
• Patients treated with V/GJ for obstructing DU: close 2-year clinical follow-up mandatory to ensure no missed cancer

Complications

Recent Evidence (2024–2026)

1. EUS-GE vs. duodenal stenting for malignant GOO (PMID 39465748): Jain et al., Medicine, 2024 — compared EUS-guided gastroenterostomy vs. SEMS; EUS-GE shows comparable or superior outcomes with lower reintervention rates.
2. EUS-GE for benign GOO (PMID 39761155): Canakis et al., J Clin Gastroenterol, 2026 — meta-analysis confirming efficacy of EUS-GE for benign GOO; still requires further standardization before routine adoption.
3. EUS-GJ vs. surgical GJ for malignant GOO (PMID 41558906): Maida et al., Dig Liver Dis, 2026 — EUS-guided gastroenterostomy is emerging as a competitive alternative to surgical gastrojejunostomy for malignant GOO, with comparable efficacy and potentially less morbidity.

⚠️ These recent meta-analyses suggest EUS-GE is gaining ground as an alternative to both open/laparoscopic surgery and luminal stenting in carefully selected patients — a shift from what older textbook editions describe.

Key Surgical Takeaways

• V/A = gold standard for benign obstructing duodenal ulcer; V/GJ is a good laparoscopic alternative with slightly higher recurrence/reintervention risk
• Always biopsy and exclude malignancy before committing to a benign ulcer repair procedure
• Duodenal stump management is a critical technical challenge — have a bailout plan
• Malignant GOO management hinges on expected survival and resectability: short survival → SEMS; longer survival/operable → surgical or EUS-guided GJ
• Biliary obstruction must be addressed first (PTC or biliary stent) before duodenal stenting
• Electrolyte correction (hypokalemic hypochloremic alkalosis) before any operative intervention is mandatory

• Color-coded section headers and structured tables
• Etiology table with relative frequencies
• Investigations table with roles and notes
• V/A vs. V/GJ comparison table
• Decision framework for malignant GOO
• Complications table with management notes
• Recent evidence (2024–2026 meta-analyses)
• Key surgical takeaways summary
• Source citations at the footer